Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Two Year Update of Phase II Trial of Pembrolizumab, Lenalidomide and Dexamethasone As Post -Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Meena Bansal, DO, David S. Siegel, Jaeil Ahn, PhD, Rena Feinman, PhD, David H. Vesole, MD PhD, Joshua R Richter, MD, Andrew L. Pecora, MD, Elli Gourna Paleoudis, PhD, Scott D. Rowley, MD, Michele L. Donato, MD, Robert Korngold, PhD, Palka Anand, RN, BSN, CCRP, Laura McBride, RN, BSN, OCN, Kristin Ivanovski, RN, BSN, CCRP, Noa Biran, MD

Blood (2019) 134 (Supplement_1): 1911.

https://doi.org/10.1182/blood-2019-125155

Published: 2019

Journal Articles

Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients

Sudarsan Kollimuttathuliam, MD, Phyllis McKiernan, David S. Siegel, Scott D. Rowley, MD, Noa Biran, MD, David H. Vesole, MD PhD, Themba Nyirenda, PhD, Andrew L. Pecora, MD, Stuart L. Goldberg, MD, Andre Goy, MD, Michele L. Donato, MD

Blood (2019) 134 (Supplement_1): 4576.

https://doi.org/10.1182/blood-2019-132052

Published: 2019

Journal Articles

Sustained Hematopoietic Recovery after Salvage Autologous Stem Cell Transplants after Long Term Storage of Cryopreserved Hematopoietic Progenitor Stem Cells (HPSC)

Sarah S. Makhani, BA, Ronit Reich-Slotky, PhD, Pashna N. Munshi, MD, Noa Biran, MD, Michele L. Donato, MD, Stuart L. Goldberg, MD, Andrew L. Pecora, MD, David S. Siegel, David H. Vesole, MD PhD, Scott D. Rowley, MD

Blood (2019) 134 (Supplement_1): 4475.

https://doi.org/10.1182/blood-2019-122111

Published: 2019

Journal Articles

Cpit (Check Point Inhibitor Trial) 002: Phase I Study of Single-Agent and Combined Checkpoint Inhibition (CI) after Allogenic Hematopoietic Stem Cell Transplantation (alloHCT) in Patients at High Risk for Post-Transplant Recurrence

Jamie Koprivnikar, MD, James K McCloskey, MD, Rena Feinman, PhD, Robert Korngold, PhD, Michele L. Donato, MD, Scott D. Rowley, MD, Themba Nyirenda, PhD, Andrew L. Pecora, MD

Blood (2019) 134 (Supplement_1): 5618.

https://doi.org/10.1182/blood-2019-132025

Published: 2019

Journal Articles

Evomela® Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation

Marshall McKenna, MD, Phyllis McKiernan, David S. Siegel, Scott D. Rowley, MD, Noa Biran, MD, David H. Vesole, MD PhD, Stuart L. Goldberg, MD, Themba Nyirenda, PhD, Andrew L. Pecora, MD, Andre Goy, MD, Michele L. Donato, MD

Blood (2019) 134 (Supplement_1): 3316.

https://doi.org/10.1182/blood-2019-132114

Published: 2019

Journal Articles

Largest Reported Series of Adults Who Received Treatment with Eculizumab (ECU) for Hematopoietic Cell Transplantation-Associated Thrombotic Microangiopathy (TA-TMA). a Single Center Experience

Alan P Skarbnik, MD, Mary E Dilorenzo, APN, Michele Simone, APN, Scott D. Rowley, MD, David H. Vesole, MD PhD, Maribel Pereiras, Pharm D, Tracy Andrews, MSc, Andrew L. Pecora, MD, Michele L. Donato, MD

Blood (2018) 132 (Supplement 1): 3383.

https://doi.org/10.1182/blood-2018-99-113639

Published: 2018

Journal Articles

Influence of the Gut Microbiome on Clinical Outcomes in the CPIT-001 Trial, a Phase Ib-IIA Study of Combined Checkpoint Inhibition with Nivolumab and Ipilimumab after Autologous Hematopoietic Stem Cell Transplantation in Patients at High-Risk for Post-Transplant Recurrence

Rena Feinman, PhD, Tracy Andrews, MSc, Iriana Colorado, MSc, Joshua Zenreich, Suzanne Kosky, BS, Themba Nyirenda, PhD, Noa Biran, MD, David S Siegel, MD PhD, David H. Vesole, MD PhD, Michele L. Donato, MD, Scott D. Rowley, MD, Pashna N. Munshi, MD, Michael B Atkins, MD, Tatyana A. Feldman, MD, Lori A. Leslie, MD, Andre Goy, MD, Robert Korngold, PhD, Alan P Skarbnik, MD, Andrew L. Pecora, MD

Blood (2018) 132 (Supplement 1): 3443.

https://doi.org/10.1182/blood-2018-99-117669

Published: 2018

Journal Articles

Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma

Noa Biran, MD, Shijia Zhang, MD PhD, Scott D. Rowley, MD, David H. Vesole, MD PhD, Michele L. Donato, MD, Alan P Skarbnik, MD, Joshua R Richter, MD, Andrew L. Pecora, MD, David S Siegel, MD PhD

Blood (2018) 132 (Supplement 1): 2154.

https://doi.org/10.1182/blood-2018-99-114832

Published: 2018

Journal Articles

Comparison of Peripheral Blood Stem Cell Mobilization for Multiple Myeloma Patients over 70 Years of Age with Younger Patients

Ning Dong, MD, David S Siegel, MD PhD, Phyllis McKiernan, Noa Biran, MD, Alan P Skarbnik, MD, David H. Vesole, MD PhD, Andrew L. Pecora, MD, Scott D. Rowley, MD, Michele L. Donato, MD

Blood (2018) 132 (Supplement 1): 4554.

https://doi.org/10.1182/blood-2018-99-117498

Published: 2018

Journal Articles

Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematological Malignancies — CPIT-001 Trial

Alan P Skarbnik, MD, Michele L. Donato, MD, Robert Korngold, PhD, Rena Feinman, PhD, Scott D. Rowley, MD, Andre Goy, MD, David H. Vesole, MD PhD, Pashna N. Munshi, MD, David S Siegel, MD PhD, Tatyana A. Feldman, MD, Noa Biran, MD, Lori A. Leslie, MD, Michael B Atkins, MD, Andrew L. Pecora, MD

Blood (2018) 132 (Supplement 1): 256.

https://doi.org/10.1182/blood-2018-99-113586

Published: 2018

Journal Articles

Evaluation of Treg and Memory T Cell Profiles, Post-ASCT with Early Combination Nivolumab/Ipilimumab Therapy, in Patients with Multiple Myeloma (MM) and Diffuse Large B Cell Lymphoma (DLBCL)

Dante B. Descalzi-Montoya, PhD, Zheng Yang, MS, Kira Goldgirsh, MS, Rena Feinman, PhD, Stacey L. Fanning, PhD, David H. Vesole, MD PhD, Pashna N. Munshi, MD, Michael B Atkins, MD, Scott D. Rowley, MD, Noa Biran, MD, David S Siegel, MD PhD, Andre Goy, MD, Tatyana A. Feldman, MD, Lori A. Leslie, MD, Michele L. Donato, MD, Alan P Skarbnik, MD, Andrew L. Pecora, MD, Robert Korngold, PhD

Blood (2018) 132 (Supplement 1): 3421.

https://doi.org/10.1182/blood-2018-99-120240

Published: 2018

Journal Articles

Prospective Analysis of Bortezomib, Fludarabine and Melphalan As Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation for Multiple Myeloma

Phyllis McKiernan, David S Siegel, MD PhD, David H. Vesole, MD PhD, Tracy Andrews, MSc, Noa Biran, MD, Scott D. Rowley, MD, Alan P Skarbnik, MD, Andrew L. Pecora, MD, Jacquelyn Callahan, RN, Andrea Ortega, RN, Mariefel Vendivil, RN, Supreet Kaur, MD, Marshall McKenna, MD, Michele L. Donato, MD

Blood (2018) 132 (Supplement 1): 1020.

https://doi.org/10.1182/blood-2018-99-117313

Published: 2018

Journal Articles

Preliminary Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (I) and Nivolumab (N) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematologic Malignancies - Cpit-001 Trial

Blood (2017) 130 (Supplement 1): 340.

https://doi.org/10.1182/blood.V130.Suppl_1.340.340

Published: 2017

Journal Articles

Cyclophosphamide Based Regimens Compared to Plerixafor-Based Regimens for Stem Cell Mobilization in Patients with Multiple Myeloma Result in Higher CD34+ Cell Yield, Lower Cost and Similar Outcome Post Autologous Transplantation

Rima M Panchal, MD, Phyllis McKiernan, APN, MSN, David Siegel, MD PhD, Scott D. Rowley, MD, David H. Vesole, MD PhD, Tracy Andrews, PhD, Andrea Ortega, RN, Alan P Skarbnik, MD, Noa Biran, MD, Joshua R Richter, MD, Nino Aleksidze, MD, Andrew L. Pecora, MD, Andre Goy, MD, Maribel Pereiras, Pharm D, Michele L. Donato, MD

Blood (2017) 130 (Supplement 1): 3283.

https://doi.org/10.1182/blood.V130.Suppl_1.3283.3283

Published: 2017

Journal Articles

Risk of Engraftment Syndrome after Autologous Stem Cell Transplantation for Multiple Myeloma Increases with Age and Lower Dose of CD34+ Cells, but Is Not Impacted By Immunomodulatory Chemotherapy

Phyllis McKiernan, APN, MSN, David Siegel, MD PhD, Scott D. Rowley, MD, David H. Vesole, MD PhD, Tracy Andrews, PhD, Andrea Ortega, RN, Alan P Skarbnik, MD, Noa Biran, MD, Joshua R Richter, MD, Andrew L. Pecora, MD, Andre Goy, MD, Rima M Panchal, MD, Nino Aleksidze, MD, Michele L. Donato, MD

Blood (2017) 130 (Supplement 1): 3284.

https://doi.org/10.1182/blood.V130.Suppl_1.3284.3284

Published: 2017

Journal Articles

High Expression of FGF2/SDC1 Signaling Contributes to Poor Clinical Outcome in Hodgkin Lymphoma Patients and SDC1 siRNA Suppresses Proliferation, Migration, and Invasion in Hodgkin Lymphoma Cells

Blood (2017) 130 (Supplement 1): 1483.

https://doi.org/10.1182/blood.V130.Suppl_1.1483.1483

Published: 2017

Journal Articles

Early Regulatory and Memory T Cell Profiles Post-ASCT in the Presence of Checkpoint Inhibitor (Nivolimumab+Ipilimumab) Double Therapy in Patients with High-Risk Multiple Myeloma

Dante Descalzi-Montoya, PhD, Kira Goldgirsh, MS, Zheng Yang, MS, Eugenia Dziopa, MS, Iriana Colorado, MS, Rena Feinman, PhD, Themba Nyirenda, PhD, David H. Vesole, MD, Pashna N. Munshi, MD, Scott D. Rowley, MD, Noa Biran, MD, Joshua R Richter, MD, David Siegel, MD PhD, Michele L. Donato, MD, Alan P Skarbnik, MD, Andrew L. Pecora, MD, Robert Korngold, PhD

Blood (2017) 130 (Supplement 1): 1862.

https://doi.org/10.1182/blood.V130.Suppl_1.1862.1862

Published: 2017

Journal Articles

Outcomes of Autologous Stem Cell Transplantation in Very Elderly Patients with Multiple Myeloma

Phyllis McKiernan, APN, MSN, David Siegel, MD PhD, David H. Vesole, MD PhD, Scott D. Rowley, MD, Tracy Andrews, PhD, Andrea Ortega, RN, Alan P Skarbnik, MD, Noa Biran, MD, Joshua R Richter, MD, Andrew L. Pecora, MD, Andre Goy, MD, Rima M Panchal, MD, Nino Aleksidze, MD, Michele L. Donato, MD

Blood (2017) 130 (Supplement 1): 2013.

https://doi.org/10.1182/blood.V130.Suppl_1.2013.2013

Published: 2017

Journal Articles

Incidence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients with Multiple Myeloma

Joshua R Richter, MD, Noa Biran, MD, Dhakshila Paramanathan, Srikesh Arunajadai, PhD, Victoria DeVincenzo, Ruth Pe Benito, Brooke Gruman, Sukhi Kaur, John Hervey, Eric Schultz, Scott Paddock, Andrew L. Pecora, MD, David H. Vesole, MD, David Siegel, MD PhD, Stuart L. Goldberg, MD

Blood (2017) 130 (Supplement 1): 679.

https://doi.org/10.1182/blood.V130.Suppl_1.679.679

Published: 2017

Journal Articles

Patients Responding to Any First Line Therapy for Multiple Myeloma Should Proceed to Autologous Stem Cell Transplantation Instead of Receiving Second Line Therapy to Deepen Response

Nino Aleksidze, MD, Phyllis McKiernan, APN, MSN, David Siegel, MD PhD, Scott D. Rowley, MD, David H. Vesole, MD PhD, Tracy Andrews, PhD, Andrea Ortega, RN, Alan P Skarbnik, MD, Noa Biran, MD, Joshua R Richter, MD, Andrew L. Pecora, MD, Andre Goy, MD, Rima M Panchal, MD, Michele L. Donato, MD

Blood (2017) 130 (Supplement 1): 4538.

https://doi.org/10.1182/blood.V130.Suppl_1.4538.4538

Published: 2017

NARROW

Two Year Update of Phase II Trial of Pembrolizumab, Lenalidomide and Dexamethasone As Post -Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients

Sustained Hematopoietic Recovery after Salvage Autologous Stem Cell Transplants after Long Term Storage of Cryopreserved Hematopoietic Progenitor Stem Cells (HPSC)

Cpit (Check Point Inhibitor Trial) 002: Phase I Study of Single-Agent and Combined Checkpoint Inhibition (CI) after Allogenic Hematopoietic Stem Cell Transplantation (alloHCT) in Patients at High Risk for Post-Transplant Recurrence

Evomela® Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation

Largest Reported Series of Adults Who Received Treatment with Eculizumab (ECU) for Hematopoietic Cell Transplantation-Associated Thrombotic Microangiopathy (TA-TMA). a Single Center Experience

Influence of the Gut Microbiome on Clinical Outcomes in the CPIT-001 Trial, a Phase Ib-IIA Study of Combined Checkpoint Inhibition with Nivolumab and Ipilimumab after Autologous Hematopoietic Stem Cell Transplantation in Patients at High-Risk for Post-Transplant Recurrence

Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma

Comparison of Peripheral Blood Stem Cell Mobilization for Multiple Myeloma Patients over 70 Years of Age with Younger Patients

Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematological Malignancies — CPIT-001 Trial

Evaluation of Treg and Memory T Cell Profiles, Post-ASCT with Early Combination Nivolumab/Ipilimumab Therapy, in Patients with Multiple Myeloma (MM) and Diffuse Large B Cell Lymphoma (DLBCL)

Prospective Analysis of Bortezomib, Fludarabine and Melphalan As Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation for Multiple Myeloma

Preliminary Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (I) and Nivolumab (N) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematologic Malignancies - Cpit-001 Trial

Cyclophosphamide Based Regimens Compared to Plerixafor-Based Regimens for Stem Cell Mobilization in Patients with Multiple Myeloma Result in Higher CD34+ Cell Yield, Lower Cost and Similar Outcome Post Autologous Transplantation

Risk of Engraftment Syndrome after Autologous Stem Cell Transplantation for Multiple Myeloma Increases with Age and Lower Dose of CD34+ Cells, but Is Not Impacted By Immunomodulatory Chemotherapy

High Expression of FGF2/SDC1 Signaling Contributes to Poor Clinical Outcome in Hodgkin Lymphoma Patients and SDC1 siRNA Suppresses Proliferation, Migration, and Invasion in Hodgkin Lymphoma Cells

Early Regulatory and Memory T Cell Profiles Post-ASCT in the Presence of Checkpoint Inhibitor (Nivolimumab+Ipilimumab) Double Therapy in Patients with High-Risk Multiple Myeloma

Outcomes of Autologous Stem Cell Transplantation in Very Elderly Patients with Multiple Myeloma

Incidence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients with Multiple Myeloma

Patients Responding to Any First Line Therapy for Multiple Myeloma Should Proceed to Autologous Stem Cell Transplantation Instead of Receiving Second Line Therapy to Deepen Response

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only